Radiation oncologist Anatoly Nikolaev, MD, has joined the medical staff at Cleveland Clinic Florida [1, 2].
His arrival expands the facility's capacity to treat high-complexity malignancies and advances clinical research into how tumors resist standard medical treatments. This specialization is critical for patients facing advanced stages of cancer where traditional therapies may fail.
Nikolaev provides radiation therapy for several specific cancer types, including prostate cancer, and head and neck cancer [1, 2]. His expertise also extends to treating central nervous system disease sites and brain metastases [1, 2]. These conditions often require precise targeting to avoid damaging healthy surrounding tissue.
Beyond direct patient care, Nikolaev is tasked with conducting specialized research at the center [1, 2]. His work focuses on the mechanisms of resistance to radiation, chemotherapy, and immunotherapy [1, 2]. Understanding why some cancers do not respond to these treatments is a primary goal of his clinical practice.
By integrating this research with active patient treatment, the center aims to develop more effective protocols for resistant tumors. The focus on immunotherapy resistance is particularly relevant as these biological therapies become more common in oncology.
Cleveland Clinic Florida continues to recruit specialists to bolster its cancer center's multidisciplinary approach [2]. The addition of a radiation oncologist with a research focus allows the institution to bridge the gap between laboratory findings and bedside care.
“Nikolaev provides radiation therapy for several specific cancer types, including prostate cancer, and head and neck cancer.”
The appointment of Dr. Nikolaev signals a strategic move by Cleveland Clinic Florida to prioritize 'translational medicine'—the process of turning laboratory research into patient treatments. By focusing on resistance mechanisms, the center is positioning itself to handle the most difficult cases of cancer that have failed first-line therapies, potentially making it a referral hub for refractory oncology cases in the region.





